Molecular Oncology (Feb 2019)

BCG‐induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling

  • Cristián Ibarra,
  • Marie Karlsson,
  • Simone Codeluppi,
  • Manuel Varas‐Godoy,
  • Songbai Zhang,
  • Lauri Louhivuori,
  • Sara Mangsbo,
  • Arad Hosseini,
  • Navid Soltani,
  • Rahim Kaba,
  • T. Kalle Lundgren,
  • Abolfazl Hosseini,
  • Nobuyuki Tanaka,
  • Mototsugu Oya,
  • Peter Wiklund,
  • Ayako Miyakawa,
  • Per Uhlén

DOI
https://doi.org/10.1002/1878-0261.12397
Journal volume & issue
Vol. 13, no. 2
pp. 202 – 211

Abstract

Read online

Bacillus Calmette–Guérin (BCG) is widely used in the clinic to effectively treat superficial urinary bladder cancer. However, a significant proportion of patients who fail to respond to BCG risk cystectomy or death. Though more than 3 million cancer treatments with BCG occur annually, surprisingly little is known about the initial signaling cascades activated by BCG. Here, we report that BCG induces a rapid intracellular Ca2+ (calcium ion) signal in bladder cancer cells that is essential for activating the transcription factor nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) and for synthesizing and secreting proinflammatory cytokines, including interleukin 8 (IL‐8). A similar Ca2+ response was observed when cells were exposed to the supernatant of BCG. Studying cellular molecular mechanisms involved in the BCG signaling event, we found pivotal roles for phospholipase C and the Toll‐like receptor 4. Further assessment revealed that this signaling pathway induces synthesis of IL‐8, whereas exocytosis appeared to be controlled by global Ca2+ signaling. These results shed new light on the molecular mechanisms underlying BCG treatment of bladder cancer, which can help in improving therapeutic efficacy and reducing adverse side effects.

Keywords